West Pharmaceutical Services, Inc. (WST) Earnings Call Transcripts

West Pharmaceutical Services, Inc.'s Latest Earnings Call - September 14, 2026

In Q2 2026, West Pharmaceutical Services (WST:US) reported a robust 13% revenue growth, surpassing expectations despite a cyber incident. The company achieved earnings growth driven by strong performance in its HPP business, which grew 18%, and raised its full-year organic revenue guidance to 10-11%, up 250 basis points from prior estimates. This positive momentum, particularly in the GLP-1 segment, positions West favorably for continued growth in the second half of the fiscal year.

Reported metrics

Guidance from management

Management raised full-year organic revenue guidance to 10-11%, reflecting confidence in continued strong demand across business segments.

What management said

Yes. As we've done all year, we've got an upside bias to our forecast for GLP-1. So I would say there's nothing fundamentally that we see in the market that has changed and feel good about the rest of the year for GLP-1s.

Yes, they do. They typically have the same primary containment for a couple of reasons. One is speed to market, so they don't want to have to do additional testing. It also has additional cost to prove equivalency if you do change that out for a relatively small piece of the COGS, you typically don't see that. And we also see very high participation rate from West in the biosimilars. So if we're on the innovator drug...

What analysts pressed on

Analysts expressed concerns regarding the impact of the cyber incident on future performance and the potential for deceleration in GLP-1 growth. There were questions about how quickly the company could recover lost revenues and maintain momentum in the second half of the year.

Main topics on the call

• Revenue Growth Acceleration — West achieved a 13% growth in revenue for Q2, exceeding expectations. CFO Robert McMahon stated, "We were really, really pleased with how Q2 shaped up despite the fact of the cyber incident."
• HPP Business Performance — The HPP business, which constitutes nearly 50% of total revenues, grew 18% in Q2, driven by demand for both GLP-1s and non-GLP-1 products. McMahon noted, "Our GLP-1 business continues to perform very well for us."
• Guidance Increase — Management raised full-year organic revenue guidance to 10-11%, reflecting strong demand and operational recovery. McMahon commented, "As a result of that strong Q2, we actually raised our full year guidance for the -- t...
• Impact of Cyber Incident — The cyber incident had a temporary impact on operations, particularly in the West Vantage business, which saw a 1% growth. McMahon indicated that they expect to recover about $7 million in revenues in Q3 and Q4.

Read the full West Pharmaceutical Services, Inc. transcript (September 14, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 79 West Pharmaceutical Services, Inc. earnings call transcripts on record, spanning January 16, 2020 to September 14, 2026. Based on this history, West Pharmaceutical Services, Inc. reports quarterly. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

WST

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

79

First call

January 16, 2020

Most recent

September 14, 2026

Reporting cadence

quarterly